AtriCure (ATRC) Research & Development (2010 - 2026)

AtriCure (ATRC) has 17 years of Research & Development data on file, last reported at $24.2 million in Q1 2026.

• On a quarterly basis, Research & Development rose 7.58% year-over-year to $24.2 million in Q1 2026; TTM through Mar 2026 was $100.9 million, a 2.08% increase from a year earlier, with the FY2025 full-year figure at $99.2 million, up 3.15% from the prior year.
• Research & Development for Q1 2026 stood at $24.2 million, down from $24.5 million in the prior quarter.
• Over the last five years, Research & Development for ATRC reached as high as $35.0 million in Q4 2024 and fell as low as $13.6 million in Q1 2022.
• Historically, Research & Development has averaged $20.6 million across 5 years, with a median of $20.4 million in 2024.
• Across the five-year window, Research & Development surged 68.09% in 2024 and dropped 29.9% in 2025, its largest moves.
• Year by year, Research & Development stood at $13.7 million in 2022, then jumped by 51.27% to $20.8 million in 2023, then jumped by 68.09% to $35.0 million in 2024, then decreased by 29.9% to $24.5 million in 2025, then retreated by 1.1% to $24.2 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $24.2 million in Q1 2026, $24.5 million in Q4 2025, and $22.9 million in Q3 2025.